BUZZ-Protara <a href="https://laohu8.com/S/LENZ">Therapeutics</a> gains on mid-stage data on bladder cancer therapy** Shares of biotech firm Protara Therapeutics TARA.O rise 50% to $5.32 premarket
** Co says its experimental cell therapy to treat a type of bladder cancer helped remove all signs of cancer in 72% of patients at six months of treatment in an open-label mid-stage study
** The therapy, TARA-002, showed a favorable safety and tolerability profile and no patients discontinued due to side-effects - TARA
** TARA-002 is being developed to treat high-risk non-muscle invasive bladder cancer (NMIBC)
** Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing ~80% of bladder cancer diagnoses -TARA
** Up to last close, stock up ~89% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.